# Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma

> **NCT00484601** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 9 (actual)

## Conditions studied

- Refractory Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Ifosfamide
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT00484601
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-04-15
- **Primary completion:** 2007-11-07
- **Final completion:** 2007-11-07
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Low accrual.
- **Last updated:** 2019-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00484601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00484601, "Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00484601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*